BioMark Diagnostics Inc.
BMKDF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $24,199 | $24,204 | $15,943 | $15,823 |
| - Cash | $2,482 | $157 | $72 | $383 |
| + Debt | $454 | $1,546 | $1,651 | $1,049 |
| Enterprise Value | $22,171 | $25,593 | $17,522 | $16,489 |
| Revenue | $154 | $163 | $153 | $44 |
| % Growth | -5.5% | 6.3% | 249.4% | – |
| Gross Profit | $154 | $163 | $153 | $44 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$1,464 | -$919 | -$1,346 | -$1,225 |
| % Margin | -949.6% | -563.1% | -876.8% | -2,787.4% |
| Net Income | -$1,927 | -$1,427 | -$1,842 | -$1,454 |
| % Margin | -1,249.7% | -874.5% | -1,200.2% | -3,309.4% |
| EPS Diluted | -0.02 | -0.017 | -0.022 | -0.02 |
| % Growth | -19.8% | 25.1% | -10.9% | – |
| Operating Cash Flow | -$1,093 | -$983 | -$914 | -$1,204 |
| Capital Expenditures | -$4 | -$4 | -$5 | -$59 |
| Free Cash Flow | -$1,097 | -$987 | -$920 | -$1,263 |